동맥경화성 심혈관질환(ASCVD) : 시장 인사이트, 역학, 시장 예측(2034년)

Atherosclerotic Cardiovascular Disease (ASCVD) - Market Insight, Epidemiology And Market Forecast - 2034

US $ 7,950 ￦ 11,502,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 11,925 ￦ 17,254,000

PDF (2-3 User License)

PDF 보고서를 동일 사업장에서 3명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 15,900 ￦ 23,005,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 23,850 ￦ 34,508,000

PDF (Global License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

주요 하이라이트

• 2023년 동맥경화성 심혈관질환(ASCVD) 시장 규모는 7대 주요 시장 중 미국이 가장 큰 시장으로 약 120억 달러에 달했습니다.
• 2023년 동맥경화성 심혈관질환(ASCVD) 진단을 받은 유병자 수는 7대 시장 중 미국이 약 2,600만 명으로 가장 많았으며, 2034년까지 더 늘어날 것으로 예측됩니다.
• 2023년 미국에서는 1,400만 명 이하의 남성과 11,000명 이하의 여성이 동맥경화성 심혈관 질환(ASCVD)을 앓고 있을 것으로 예상됩니다.
• ASCVD 시장은 유병률 증가, 치료의 발전, 정부의 구상에 힘입어 성장하고 있지만, 높은 비용, 엄격한 규제, 환자 순응도 문제 등의 장벽에 직면해 있습니다. 상환은 다양하며, 예방적 조치와 약가 협상에 중점을 두고 있습니다. 미충족 수요에는 효과적인 장기 관리, 첨단 치료에 대한 광범위한 접근성, 표적 치료를 위한 맞춤 치료 접근법 등이 포함됩니다.
• 현재 동맥경화성 심혈관질환(ASCVD) 시장은 스타틴, 에제티미브/벤페도산과 그 병용요법, PCSK9i를 포함하며, 2023년 주요 7대 시장 규모는 230억 달러에 달할 것으로 예상됩니다. 예측 기간(2024-2034년) 동안 새로운 치료제가 출시될 것으로 예상됨에 따라 시장 규모는 연평균 2.2% 성장할 것으로 예상됩니다.
• 일본의 동맥경화성 심혈관 질환(ASCVD) 시장 규모는 2023년 30억 달러로 2034년까지 상당한 CAGR로 상승할 것으로 예상됩니다.
• 동맥경화성 심혈관 질환 치료제 시장의 총 시장 규모는 Olpasiran, MK-0616, Obicetrapib과 같은 새로운 효과적인 치료제의 등장으로 예측 기간 중 성장할 것으로 예상됩니다.

동맥경화성 심혈관질환(ASCVD) 시장 전망

동맥경화성 심혈관질환(ASCVD)의 치료는 심혈관 위험을 줄이고 근본적인 동맥경화증을 관리하는 데 중점을 두고 있습니다. 심장에 좋은 식습관, 규칙적인 신체활동, 금연, 체중 조절과 같은 생활습관 개선은 고혈압, 당뇨병, 고지혈증과 같은 위험요인을 조절하는 데 있으며, 기본이 됩니다.

스타틴은 저밀도 지단백 콜레스테롤(LDL-C)을 낮추기 위한 1차 선택 약물이며, 고위험군 환자에게는 고비중 스타틴이 권장됩니다. 스타틴 불내성이 있거나 효과가 불충분한 환자에게는 에제티미브나 PCSK9 억제제와 같은 비스타틴 요법이 추가됩니다. 항혈소판 요법, 일반적으로 아스피린은 ASCVD가 확립된 환자의 혈전성 사건을 예방하기 위해 처방되며, ACE 억제제 및 ARB와 같은 강압제를 이용한 혈압 조절은 심혈관 합병증을 줄이는 데 필수적입니다. 급성관상동맥증후군이나 심각한 관상동맥 협착의 경우 경피적 관상동맥중재술(PCI)이나 관상동맥우회술(CABG)과 같은 혈행재건술이 필요합니다.

ASCVD의 장기적인 관리를 위해서는 지속적인 모니터링과 치료 및 생활습관 개선에 대한 환자 교육이 필수적입니다.

• 7대 주요 시장의 동맥경화성 심혈관 질환(ASCVD) 시장 규모는 2023년 최대 23억 3,370만 달러에 달할 것으로 예상되며, 예측 기간 중 더욱 확대될 것으로 보입니다.
• 미국은 다른 주요 시장인 유럽 4개국(독일, 프랑스, 이탈리아, 이탈리아, 스페인), 영국, 일본과 비교했을 때, 2023년 7대 주요 시장 중 가장 큰 시장으로 전체 ASCVD 시장 규모의 약 52%를 차지할 것으로 예상됩니다.
• EU 국가 중에서는 독일이 가장 시장 규모가 크고, 2023년에 약 22억 7,500만 달러에 달했습니다. 영국은 최소 시장 규모로, 2023년에 최대 13억 2,500만 달러입니다.
• 일본의 ASCVD 시장 규모는 2023년에 30억 5,800만 달러로 추정됩니다.
• 올파시란(Olpasiran, 구 AMG 890), 오비세트라핍(TA-8995), MK-0616 등 향후 치료제의 출시가 예상됨에 따라 동맥경화성 심혈관질환(ASCVD)의 총 시장 규모는 향후 수년간 변화를 보일 것으로 예상됩니다.

동맥경화성 심혈관질환(ASCVD)의 주요 7 시장(미국, 독일, 스페인, 이탈리아, 프랑스, 영국, 일본)에 대해 조사분석했으며, 각 지역의 시장 규모, 현재 치료법, 미충족 요구, 신약 등의 정보를 제공하고 있습니다.

목차

제1장 주요 인사이트

제2장 리포트 서론

제3장 동맥경화성 심혈관질환(ASCVD) 시장의 개요 : 치료법별

• ASCVD의 시장 점유율 분포 : 치료법별(2020년)
• ASCVD의 시장 점유율 분포 : 치료법별(2034년)

제4장 ASCVD 역학과 시장의 조사 방법

제5장 동맥경화성 심혈관질환(ASCVD)의 개요

제6장 주요 이벤트

제7장 질환의 배경과 개요 : ASCVD

• 서론
• 관련 질환
• 동맥경화증 병태생리학
• ASCVD의 위험 요인
• ASCVD의 증상
• 진단
• 치료

제8장 역학과 환자 인구

• 주요 조사 결과
• 전제조건과 근거 : 주요 7 시장
• 주요 7 시장의 ASCVD로 진단된 총유병자 수
• 미국
• 유럽 4개국·영국
• 일본

제9장 환자 여정

제10장 출시 약품

• 주요 경쟁
• LEQVIO(inclisiran) : Novartis Pharmaceuticals Corporation
• XARELTO(rivaroxaban) : Bayer/Johnson & Johnson

제11장 신약

• 주요 경쟁
• Olpasiran(AMG 890) : Amgen Inc.
• MK-0616 : Merck Sharp & Dohme Corp.
• Obicetrapib(TA-8995) : NewAmsterdam Pharma

제12장 ASCVD : 시장 분석

• 주요 조사 결과
• 주요 시장 예측의 전제조건
• 시장 전망
• 컨조인트 분석
• 주요 7 시장의 ASCVD 전체 시장 규모
• 주요 7 시장의 ASCVD 시장 규모 : 치료법별
• 미국의 ASCVD 시장 규모
  • ASCVD 전체 시장 규모
  • 미국의 ASCVD 시장 규모 : 치료법별
• 유럽 4개국·영국의 ASCVD 시장 규모
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 영국
• 일본의 ASCVD 시장 규모
  • 일본의 ASCVD 시장 규모 : 치료법별

제13장 KOL의 견해

제14장 SWOT 분석

제15장 미충족 요구

제16장 시장 참여와 상환

• 미국
• 유럽 4개국·영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 영국
• 일본

제17장 부록

제18장 리포트 조사 방법

제19장 DelveInsight 서비스 내용

제20장 면책사항

KSA

영문 목차

영문목차

Key Highlights:

• In 2023, the market size of Atherosclerotic Cardiovascular Disease (ASCVD) was highest in the US among the 7MM, accounting for approximately USD 12 billion which is further expected to rise at a CAGR of 2.8% by 2034.
• In 2023, the diagnosed prevalence of Atherosclerotic Cardiovascular Disease (ASCVD) was highest in the US among the 7MM, accounting for nearly 26 million cases which is further expected to increase by 2034.
• In the United States, in 2023, ~14 million males and ~11 thousand females were affected with Atherosclerotic Cardiovascular Disease (ASCVD).
• The ASCVD market is driven by rising prevalence, treatment advancements, and government initiatives but faces barriers like high costs, stringent regulations, and patient adherence challenges. Reimbursement varies, with a focus on preventive measures and drug price negotiations. Unmet needs include effective long-term management, broader access to advanced therapies, and personalized treatment approaches for targeted care.
• The current market of Atherosclerotic Cardiovascular Disease (ASCVD) includes statin, ezetimibe/bempoidic acid and their combinations, and PCSK9i, making up a market size of USD 23 billion in the 7MM in 2023. The market size is expected to rise at a CAGR of 2.2% with the projected launch of emerging therapies during the forecast period (2024-2034).
• The market size of Atherosclerotic Cardiovascular Disease (ASCVD) in Japan was USD 3 billion in 2023, which is expected to rise at a significant CAGR by 2034.
• The total market size of the Atherosclerotic Cardiovascular Disease treatment market is anticipated to experience growth during the forecast period due to the emergence of new and effective treatments, namely, Olpasiran, MK-0616, and Obicetrapib, among others.

DelveInsight's "Atherosclerotic Cardiovascular Disease (ASCVD) - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Atherosclerotic Cardiovascular Disease (ASCVD), historical and forecasted epidemiology as well as the Atherosclerotic Cardiovascular Disease (ASCVD) market trends in the United States, EU4 and the UK (Germany, France, Italy, Spain) and the United Kingdom, and Japan.

The Atherosclerotic Cardiovascular Disease (ASCVD) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Atherosclerotic Cardiovascular Disease (ASCVD) market size from 2020 to 2034. The Report also covers current Atherosclerotic Cardiovascular Disease (ASCVD) treatment practice, market drivers, market barriers, SWOT analysis, reimbursement and market access, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2020-2034

Disease Understanding and Treatment Algorithm

Atherosclerotic Cardiovascular Disease (ASCVD) Overview

ASCVD is a progressive and chronic condition that can affect various arteries throughout the body, including those supplying the heart (coronary arteries), brain (cerebral arteries), and legs (peripheral arteries). The most common manifestations of ASCVD include coronary artery disease (CAD), cerebrovascular disease (stroke), and peripheral arterial disease (PAD).

The development of ASCVD is influenced by a number of risk factors, such as poor diet, inactivity, cigarette use, obesity, family history, and alcohol abuse. The early stages of ASCVD are without symptoms, but later on as the artery narrows and blood flow is reduced, symptoms start to show. The type of artery that is affected and how much blood flow is impeded may also alter the symptoms. Angina, cold chills, dizziness, acute exhaustion, shortness of breath, and heart palpitations are a few typical symptoms.

Atherosclerotic Cardiovascular Disease (ASCVD) Diagnosis

In addition to symptoms, risk assessment is also used to make the diagnosis of ASCVD. Apolipoprotein E [APOE], LDLR, APOB, PCSK9, or LDLRAP1 genes; genotyping to study variations in contributing genes; and morphological examinations (ultrasonography, computed tomography, magnetic resonance imaging/angiography, or catheterization) are typically used to make a clinical diagnosis of ASCVD. Genetic testing, biomarker testing, and imaging can all be used to confirm an ASCVD diagnosis if a doctor has a suspicion. However, the cost and accessibility of genetic testing and biomarker testing may restrict their use.

Atherosclerotic Cardiovascular Disease (ASCVD) Treatment

Treatment strategies for Atherosclerotic Cardiovascular Disease occur at the population level but also engage individual adults to slow the development of ASCVD. Promoting a healthy lifestyle throughout life is the most important way to prevent ASCVD. Treatment other than lifestyle modification is based on pharmacotherapy and invasive procedures. A comprehensive patient-centered approach that addresses all aspects of a patient's lifestyle habits and estimated risk of a future ASCVD event is the first step in deciding where there may be a need for pharmacotherapy. For clinical ASCVD, revascularization procedures such as angioplasties and bypass are warranted, among others.

Atherosclerotic Cardiovascular Disease (ASCVD) Epidemiology

As the market is derived using a patient-based model, the Atherosclerotic Cardiovascular Disease (ASCVD) epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Atherosclerotic Cardiovascular Disease, (ASCVD), Gender-specific Diagnosed Prevalent Cases of Atherosclerotic Cardiovascular Disease (ASCVD), Age-specific Diagnosed Prevalent Cases of Atherosclerotic Cardiovascular Disease (ASCVD) and Comorbidity-specific Diagnosed Prevalent Cases of Atherosclerotic Cardiovascular Disease (ASCVD) in the 7MM covering, the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2020 to 2034.

• In the assessment done by DelveInsight, the estimated total diagnosed prevalent cases of Atherosclerotic Cardiovascular Disease (ASCVD) in the 7MM were nearly 55,700 thousand in 2023.
• The highest total diagnosed prevalent cases of ASCVD were accounted by the US in 2023 (26 million), which are expected to show a rise in the future.
• Among the European countries, Germany had the highest diagnosed prevalent cases of ASCVD with ~5 million cases, followed by France, which had diagnosed prevalent population of ~4 million in 2023. On the other hand, Spain had the lowest diagnosed prevalent population (3 million cases).
• Japan had nearly 8 million total diagnosed prevalent cases of ASCVD in 2023, accounting for approximately 15% in 7MM.
• The comorbidity-specific cases of ASCVD were divided into recent ACS, ischemic stroke, PAD, other CHD, and other comorbidities comprising CKD. Other CHD had the highest number of cases, 28 million in 2023 in the 7MM.
• DelveInsight's analysis indicates that among the EU4 and the UK, males were more affected than females, with approximately 12 million male cases and 8 million female cases in 2023.
• Based on age, the diagnosed prevalent population of ASCVD was divided into three groups: 18-44 year, 45-64 year, and 65+ year. In Japan, the 45-64 year age group accounted for the highest number of cases, ~5,480 thousand in 2023, followed by the 18-44 year group with 1,645 thousand cases, and the 65+ year group with ~1,100 thousand cases.

Atherosclerotic Cardiovascular Disease (ASCVD) Drug Chapters

The drug chapter segment of the Atherosclerotic Cardiovascular Disease (ASCVD) report encloses a detailed analysis of Atherosclerotic Cardiovascular Disease (ASCVD) off-label drugs and late-stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Atherosclerotic Cardiovascular Disease (ASCVD) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Marketed Drugs

LEQVIO (inclisiran): Novartis Pharmaceuticals Corporation

LEQVIO (inclisiran) is the pioneering and sole small-interfering RNA therapy designed to lower LDL cholesterol, a significant risk factor for ASCVD, a condition triggered by plaque accumulation in the arteries. It is administered by a healthcare professional through injections twice a year, with an initial dose and a follow-up dose after 3 months.

PRALUENT (alirocumab): Regeneron Pharmaceuticals/Sanofi

PRALUENT is a fully human monoclonal antibody that inhibits the binding of PCSK9 to the LDL receptor. Through inhibiting PCSK9, PRALUENT increases the number of available LDL receptors on the surface of liver cells to clear LDL, which lowers LDL cholesterol levels in the blood.

Emerging Drugs

Olpasiran (AMG 890): Amgen Inc.

Olpasiran (formerly AMG 890) is a small interfering RNA (siRNA) that lowers lipoprotein (a), also known as Lp (a). It is being investigated for treating ASCVD; the drug is administered subcutaneously as a solution. Currently, the company is recruiting for Phase III clinical trial to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants with ASCVD and elevated lipoprotein (a).

Obicetrapib (TA-8995): NewAmsterdam Pharma

Obicetrapib is a novel, selective CETP inhibitor that potently decreases low-density lipoprotein-cholesterol (LDL-C) as well as increases high-density lipoprotein-cholesterol (HDL-C) and the number of ApoA1-containing lipoproteins. The drug candidate is designed to be administered orally. Currently, the company is recruiting for Phase III clinical trials to evaluate the effect of obicetrapib on the risk of major adverse cardiovascular events (MACE), including cardiovascular (CV) death, non-fatal myocardial infarction, non-fatal stroke, or non-elective coronary revascularization.

Atherosclerotic Cardiovascular Disease (ASCVD) Market Outlook

The treatment of Atherosclerotic Cardiovascular Disease (ASCVD) focuses on reducing cardiovascular risk and managing the underlying atherosclerosis. Lifestyle modifications, including a heart-healthy diet, regular physical activity, smoking cessation, and weight management, are fundamental in controlling risk factors such as hypertension, diabetes, and hyperlipidemia.

Pharmacological therapy is also crucial; statins are the first-line treatment to lower low-density lipoprotein cholesterol (LDL-C), with high-intensity statins recommended for high-risk patients. For those with statin intolerance or inadequate response, non-statin therapies like ezetimibe or PCSK9 inhibitors may be added. Antiplatelet therapy, typically aspirin, is prescribed to prevent thrombotic events in patients with established ASCVD. Blood pressure control, using antihypertensives like ACE inhibitors or ARBs, is essential in reducing cardiovascular complications. In cases of acute coronary syndrome or significant coronary artery stenosis, revascularization procedures such as percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) may be necessary.

Ongoing monitoring and patient education on adherence to treatment and lifestyle changes are vital for long-term management of ASCVD.

• The market size of Atherosclerotic Cardiovascular Disease (ASCVD) in the 7MM was ~USD 23,370 million in 2023, which is further anticipated to increase during the forecast period.
• The United States accounted for the highest market size of ASCVD approximately 52% of the total market size in 7MM in 2023, in comparison to the other major markets i.e., EU4 countries (Germany, France, Italy, and Spain), and the United Kingdom, and Japan.
• Among the EU countries, Germany had the highest market size with nearly USD 2,275 million each in 2023, while the UK had the lowest market size for ASCVD with USD ~ 1,325 million in 2023.
• The market size for ASCVD in Japan was estimated to be about USD 3,058 million in 2023.
• With the expected launch of upcoming therapies, such as Olpasiran (formerly AMG 890), Obicetrapib (TA-8995), MK-0616, among others, the total market size of Atherosclerotic Cardiovascular Disease (ASCVD) is expected to show change in the upcoming years.

Atherosclerotic Cardiovascular Disease (ASCVD) Drugs Uptake

This section focuses on the uptake rate of potential drugs expected to launch in the market during 2020-2034. For example, MK-0616 in the US is expected to be launched by 2027 with a peak share of 1.20%. MK-0616 is anticipated to take 7 years to peak with a medium uptake.

Atherosclerotic Cardiovascular Disease (ASCVD) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Atherosclerotic Cardiovascular Disease (ASCVD) emerging therapies.

KOL Views

To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on Atherosclerotic Cardiovascular Disease (ASCVD) evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility, including KOL from Rollins School of Public Health, Emory University, Atlanta, Georgia; Department of Epidemiology and Health Monitoring, Robert Koch Institute; Cardiovascular Prevention Institute, Paris; Teikyo Academic Research Center, Teikyo University, Itabashi-ku, Tokyo, and others

Delveinsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps understand and validate current and emerging therapies, treatment patterns, or Atherosclerotic Cardiovascular Disease (ASCVD) market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

The high cost of therapies for the treatment is a major factor restraining the growth of the global drug market. Because of the high cost, the economic burden is increasing, leading the patient to escape from proper treatment.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Report:

• The report covers a segment of key events, an executive summary, descriptive overview of Atherosclerotic Cardiovascular Disease (ASCVD), explaining its causes, signs and symptoms, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines.
• Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current treatment landscape.
• A detailed review of the Atherosclerotic Cardiovascular Disease (ASCVD) market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind the approach is included in the report covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM Atherosclerotic Cardiovascular Disease (ASCVD) market.

Atherosclerotic Cardiovascular Disease (ASCVD) Report Insights

• Patient Population
• Therapeutic Approaches
• Atherosclerotic Cardiovascular Disease (ASCVD) Pipeline Analysis
• Atherosclerotic Cardiovascular Disease (ASCVD) Market Size and Trends
• Existing and Future Market Opportunity

Atherosclerotic Cardiovascular Disease (ASCVD) Report Key Strengths

• 11 years Forecast
• The 7MM Coverage
• Atherosclerotic Cardiovascular Disease (ASCVD) Epidemiology Segmentation
• Key Cross Competition
• Conjoint Analysis
• Drugs Uptake and Key Market Forecast Assumptions

Atherosclerotic Cardiovascular Disease (ASCVD) Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)

Key Questions:

Market Insights

• What was the Atherosclerotic Cardiovascular Disease (ASCVD) market share (%) distribution in 2020 and how it would look like in 2034?
• What would be the Atherosclerotic Cardiovascular Disease (ASCVD) total market size as well as market size by therapies across the 7MM during the forecast period (2024-2034)?
• What are the key findings pertaining to the market across the 7MM and which country will have the largest Atherosclerotic Cardiovascular Disease (ASCVD) market size during the forecast period (2024-2034)?
• At what CAGR, the Atherosclerotic Cardiovascular Disease (ASCVD) market is expected to grow at the 7MM level during the forecast period (2024-2034)?
• What would be the Atherosclerotic Cardiovascular Disease (ASCVD) market outlook across the 7MM during the forecast period (2024-2034)?
• What would be the Atherosclerotic Cardiovascular Disease (ASCVD) market growth till 2034 and what will be the resultant market size in the year 2034?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights

• What is the disease risk, burden, and unmet needs of Atherosclerotic Cardiovascular Disease (ASCVD)?
• What is the historical Atherosclerotic Cardiovascular Disease (ASCVD) patient population in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
• What would be the forecasted patient population of Atherosclerotic Cardiovascular Disease (ASCVD) at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Atherosclerotic Cardiovascular Disease (ASCVD)?
• Out of the above-mentioned countries, which country would have the highest prevalent population of Atherosclerotic Cardiovascular Disease (ASCVD) during the forecast period (2024-2034)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2024-2034)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies

• What are the current options for the treatment of Atherosclerotic Cardiovascular Disease (ASCVD) along with the approved therapy?
• What are the current treatment guidelines for the treatment of Atherosclerotic Cardiovascular Disease (ASCVD) in the US, Europe, And Japan?
• What are the Atherosclerotic Cardiovascular Disease (ASCVD) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
• How many companies are developing therapies for the treatment of Atherosclerotic Cardiovascular Disease (ASCVD)?
• How many emerging therapies are in the mid-stage and late stages of development for the treatment of Atherosclerotic Cardiovascular Disease (ASCVD)?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Atherosclerotic Cardiovascular Disease (ASCVD) therapies?
• What are the recent therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Atherosclerotic Cardiovascular Disease (ASCVD) and their status?
• What are the key designations that have been granted for the emerging therapies for Atherosclerotic Cardiovascular Disease (ASCVD)?
• What are the 7MM historical and forecasted market of Atherosclerotic Cardiovascular Disease (ASCVD)?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Atherosclerotic Cardiovascular Disease (ASCVD) Market.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Detailed analysis and potential of current and emerging therapies under the conjoint analysis section to provide visibility around leading emerging drugs.
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
• To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in future.
• Detailed insights on the unmet need of the existing market so that the upcoming players can strengthen their development and launch strategy.

Frequently Asked Questions:

1. What is the forecast period covered in the report?

The Atherosclerotic Cardiovascular Disease (ASCVD) Epidemiology and Market Insight report for the 7MM covers the forecast period from 2024 to 2034, providing a projection of market dynamics and trends during this timeframe.

2. Who are the key players in the Atherosclerotic Cardiovascular Disease (ASCVD) market?

The Atherosclerotic Cardiovascular Disease (ASCVD) market is quite robust. The major layers are Merck Sharp & Dohme Corp, NewAmsterdam Pharma, Amgen Inc., and others which are currently developing drugs for the treatment of Atherosclerotic Cardiovascular Disease (ASCVD).

3. How is the market size estimated in the forecast report?

The market size is estimated through data analysis, statistical modeling, and expert opinions. It may consider factors such as prevalent cases, treatment costs, revenue generated, and market trends.

4. What is the key driver of the Atherosclerotic Cardiovascular Disease (ASCVD) market?

The increase in diagnosed prevalent cases of Atherosclerotic Cardiovascular Disease (ASCVD) and the launch of emerging therapies are attributed to be the key drivers for increasing the Atherosclerotic Cardiovascular Disease (ASCVD) market.

5. What is the expected impact of emerging therapies or advancements in Atherosclerotic Cardiovascular Disease (ASCVD) treatment on the market?

Introducing new therapies, advancements in diagnostic techniques, and innovations in treatment approaches can significantly impact the Atherosclerotic Cardiovascular Disease (ASCVD) treatment market. Market forecast reports may provide analysis and predictions regarding the potential impact of these developments.

6. Does the report provide insights into the competitive landscape of the market?

The market forecast report may include information on the competitive landscape, profiling key market players, their product offerings, partnerships, and strategies, and helping stakeholders understand the competitive dynamics of the Atherosclerotic Cardiovascular Disease (ASCVD) market.

Table of Contents

1. Key Insights

2. Report Introduction

3. Atherosclerotic Cardiovascular Disease (ASCVD) Market Overview by Therapies

• 3.1. Market Share (%) Distribution of ASCVD by Therapies in 2020
• 3.2. Market Share (%) Distribution of ASCVD by Therapies in 2034

4. Methodology of ASCVD Epidemiology and Market

5. Executive Summary of Atherosclerotic Cardiovascular Disease (ASCVD)

6. Key Events

7. Disease Background and Overview: ASCVD

• 7.1. Introduction
• 7.2. Associated Diseases
• 7.3. Pathophysiology of Atherosclerosis
• 7.4. Risk Factors of ASCVD
• 7.5. Symptoms of ASCVD
• 7.6. Diagnosis
  • 7.6.1. Risk Assessment
  • 7.6.2. Diagnostic Guidelines
    • 7.6.2.1. Kaiser Permanente Washington Guideline for Management of ASCVD
    • 7.6.2.2. ACC/AHA Guidelines on the Primary Prevention of Cardiovascular Disease: 2020
    • 7.6.2.3. Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017
    • 7.6.2.4. ESC Guidelines on Cardiovascular Disease Prevention in Clinical Practice 2021
• 7.7. Treatment
  • 7.7.1. Treatment Algorithm
  • 7.7.2. Treatment Guidelines
    • 7.7.2.1. ACC/AHA Guidelines on the Primary Prevention of ASCVD
    • 7.7.2.2. Major Treatment Recommendations of the 2018 AHA/ACC Multisociety Cholesterol Guideline and the 2020 ESC/EAS Guidelines for Secondary ASCVD Prevention
    • 7.7.2.3. Kaiser Permanente Washington Guideline for the management of ASCVD
    • 7.7.2.4. Japan Atherosclerosis Society (JAS) Guidelines for the Prevention of Atherosclerotic Cardiovascular Diseases 2017
    • 7.7.2.5. ESC Guidelines on Cardiovascular Disease Prevention in Clinical Practice 2021

8. Epidemiology and Patient Population

• 8.1. Key Findings
• 8.2. Assumptions and Rationale: The 7MM
  • 8.2.1. Diagnosed Prevalent Cases of ASCVD
  • 8.2.2. Gender-specific Diagnosed Prevalent Cases of ASCVD
  • 8.2.3. Age-specific Diagnosed Prevalent Cases of ASCVD
  • 8.2.4. Comorbidity-specific Diagnosed Prevalent Cases of ASCVD
  • 8.2.5. Treatment Rate of Diagnosed ASCVD Patient
• 8.3. Total Diagnosed Prevalent Cases of ASCVD in the 7MM
• 8.4. The United States
  • 8.4.1. Total Diagnosed Prevalent Cases of ASCVD in the US
  • 8.4.2. Gender-specific Diagnosed Prevalent Cases of ASCVD in the US
  • 8.4.3. Age-specific Diagnosed Prevalent Cases of ASCVD in the US
  • 8.4.4. Comorbidity-specific Diagnosed Prevalent Cases of ASCVD in the US
• 8.5. EU4 and the UK
  • 8.5.1. Germany
    • 8.5.1.1. Total Diagnosed Prevalent Cases of ASCVD in Germany
    • 8.5.1.2. Gender-specific Diagnosed Prevalent Cases of ASCVD in Germany
    • 8.5.1.3. Age-specific Diagnosed Prevalent Cases of ASCVD in Germany
    • 8.5.1.4. Comorbidity-specific Diagnosed Prevalent Cases of ASCVD in Germany
  • 8.5.2. France
    • 8.5.2.1. Total Diagnosed Prevalent Cases of ASCVD in France
    • 8.5.2.2. Gender-specific Diagnosed Prevalent Cases of ASCVD in France
    • 8.5.2.3. Age-specific Diagnosed Prevalent Cases of ASCVD in France
    • 8.5.2.4. Comorbidity-specific Diagnosed Prevalent Cases of ASCVD in France
  • 8.5.3. Italy
    • 8.5.3.1. Total Diagnosed Prevalent Cases of ASCVD in Italy
    • 8.5.3.2. Gender-specific Diagnosed Prevalent Cases of ASCVD in Italy
    • 8.5.3.3. Age-specific Diagnosed Prevalent Cases of ASCVD in Italy
    • 8.5.3.4. Comorbidity-specific Diagnosed Prevalent Cases of ASCVD in Italy
  • 8.5.4. Spain
    • 8.5.4.1. Total Diagnosed Prevalent Cases of ASCVD in Spain
    • 8.5.4.2. Gender-specific Diagnosed Prevalent Cases of ASCVD in Spain
    • 8.5.4.3. Age-specific Diagnosed Prevalent Cases of ASCVD in Spain
    • 8.5.4.4. Comorbidity-specific Diagnosed Prevalent Cases of ASCVD in Spain
  • 8.5.5. The UK
    • 8.5.5.1. Total Diagnosed Prevalent Cases of ASCVD in the UK
    • 8.5.5.2. Gender-specific Diagnosed Prevalent Cases of ASCVD in the UK
    • 8.5.5.3. Age-specific Diagnosed Prevalent Cases of ASCVD in the UK
    • 8.5.5.4. Comorbidity-specific Diagnosed Prevalent Cases of ASCVD in the UK
• 8.6. Japan
  • 8.6.1. Total Diagnosed Prevalent Cases of ASCVD in Japan
  • 8.6.2. Gender-specific Diagnosed Prevalent Cases of ASCVD in Japan
  • 8.6.3. Age-specific Diagnosed Prevalent Cases of ASCVD in Japan
  • 8.6.4. Comorbidity-specific Diagnosed Prevalent Cases of ASCVD in Japan

9. Patient Journey

10. Marketed Drugs

• 10.1. Key Cross
• 10.2. LEQVIO (inclisiran): Novartis Pharmaceuticals Corporation
  • 10.2.1. Product Description
  • 10.2.2. Regulatory milestones
  • 10.2.3. Other Developmental Activities
  • 10.2.4. Clinical Trials Information
  • 10.2.5. Safety and Efficacy
• 10.3. XARELTO (rivaroxaban): Bayer/Johnson & Johnson
  • 10.3.1. Product Description
  • 10.3.2. Regulatory Milestones
  • 10.3.3. Other Developmental Activities
  • 10.3.4. Clinical Trials Information
  • 10.3.5. Safety and Efficacy

11. Emerging Drugs

• 11.1. Key Cross Competition
• 11.2. Olpasiran (AMG 890): Amgen Inc.
  • 11.2.1. Product Description
  • 11.2.2. Other Developmental Activities
  • 11.2.3. Clinical Trials Information
  • 11.2.4. Safety and Efficacy
  • 11.2.5. Product Profile
  • 11.2.6. Analysts' Views
• 11.3. MK-0616: Merck Sharp & Dohme Corp.
  • 11.3.1. Product Description
  • 11.3.2. Other Developmental Activity
  • 11.3.3. Clinical Trials Information
  • 11.3.4. Safety and Efficacy
  • 11.3.5. Product Profile
  • 11.3.6. Analysts' Views
• 11.4. Obicetrapib (TA-8995): NewAmsterdam Pharma
  • 11.4.1. Product Description
  • 11.4.2. Other Developmental Activities
  • 11.4.3. Clinical Trials Information
  • 11.4.4. Safety and Efficacy
  • 11.4.5. Product Profile
  • 11.4.6. Analysts' Views

12. ASCVD: Market Analysis

• 12.1. Key Findings
• 12.2. Key Market Forecast Assumptions
• 12.3. Market Outlook
• 12.4. Conjoint Analysis
• 12.5. Total Market Size of ASCVD in the 7MM
• 12.6. Market Size of ASCVD by Therapies in the 7MM
• 12.7. Market Size of ASCVD in the United States
  • 12.7.1. Total Market Size of ASCVD
  • 12.7.2. Market Size of ASCVD by Therapies in the United States
• 12.8. Market Size of ASCVD in EU4 and the UK
  • 12.8.1. Germany
    • 12.8.1.1. Total Market Size of ASCVD
    • 12.8.1.2. Market Size of ASCVD by Therapies in Germany
  • 12.8.2. France
    • 12.8.2.1. Total Market Size of ASCVD
    • 12.8.2.2. Market Size of ASCVD by Therapies in France
  • 12.8.3. Italy
    • 12.8.3.1. Total Market Size of ASCVD
    • 12.8.3.2. Market Size of ASCVD by Therapies in Italy
  • 12.8.4. Spain
    • 12.8.4.1. Total Market Size of ASCVD
    • 12.8.4.2. Market Size of ASCVD by Therapies in Spain
  • 12.8.5. The UK
    • 12.8.5.1. Total Market Size of ASCVD
    • 12.8.5.2. Market Size of ASCVD by Therapies in the UK
• 12.9. Market Size of ASCVD in Japan
  • 12.9.1. Total Market Size of ASCVD
  • 12.9.2. Market Size of ASCVD by Therapies in Japan

13. Key Opinion Leaders' Views

14. SWOT Analysis

15. Unmet Needs

16. Market Access and Reimbursement

• 16.1. The United States
  • 16.1.1. Center for Medicare and Medicaid Services (CMS)
• 16.2. EU4 and the UK
  • 16.2.1. Germany
  • 16.2.2. France
  • 16.2.3. Italy
  • 16.2.4. Spain
  • 16.2.5. The United Kingdom
• 16.3. Japan
  • 16.3.1. MHLW

17. Appendix

• 17.1. Bibliography
• 17.2. Acronyms and Abbreviations

18. Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

관련자료